4D Molecular Therapeutics Presents Phase 2 Trial Results for Wet AMD at ASRS Meeting
4D Molecular Therapeutics Presents Phase 2 Trial Results for Wet AMD at ASRS Meeting
4D Molecular Therapeutics (NASDAQ:FDMT, 4DMT or the Company), a leading clinical-stage genetic medicines company focused on unlocking the full potential of genetic medicines to treat large market diseases, today announced positive initial interim 24-week landmark data from the Population Extension cohort of the PRISM Phase 2 Clinical Trial, which evaluated intravitreal 4D-150 in a broad wet AMD patient population. The data were presented by Raj K. Maturi, M.D., in an oral presentation titled, "Phase 2 Population Extension Cohort in the PRISM Trial Evaluating 4D-150 in Adults with Neovascular Age-related Macular Degeneration," at the American Society of Retina Specialists (ASRS) Annual Scientific Meeting held in Stockholm, Sweden.
4d分子治療（納斯達克：FDMt，4DMt或公司）是一家領先的臨床階段的基因醫學公司，專注於發掘治療大型市場疾病的基因藥物的全部潛力，今天宣佈了來自PRISm第2期臨床試驗的人口擴展隊列的積極初步24周里程碑數據，評估廣泛的溼性年齡相關性黃斑變性患者群中的眼內4D-150。數據由Raj k.Maturi博士在一個口頭報告中介紹，標題爲“PRISm試驗中的第2期人口擴展隊列評估4D-150治療成人的新生血管性年齡相關性黃斑變性”，在瑞典斯德哥爾摩舉行的美國視網膜專家協會（ASRS）年度科學會議上。